IGFBP-2 and aging: a 20-year longitudinal study on IGFBP-2, IGF-I, BMI, insulin sensitivity and mortality in an aging population

in European Journal of Endocrinology
Correspondence should be addressed to A W van den Beld; Email: a.vandenbeld@erasmusmc.nl
Restricted access


Insulin-like growth factor-binding protein-2 (IGFBP-2) concentrations are low in subjects with metabolic syndrome and type 2 diabetes. Intriguingly, recent studies have demonstrated an association between high IGFBP-2 concentrations and increased mortality not only in populations with certain types of cancer, but also in relatively healthy populations. We evaluated the role of IGFBP-2 in relation to BMI and mortality.

Design and Participants

BMI, insulin sensitivity, insulin-like growth factor 1 (IGF-I) and IGFBP-2 were assessed repeatedly in 539 participants of the Baltimore Longitudinal Study of Aging around the ages of 55, 65 and 75 years.


IGFBP-2 concentrations positively correlated with insulin sensitivity and inversely with BMI, both at baseline and follow-up. Independent of IGF-I, sex, BMI and insulin sensitivity, circulating IGFBP-2 levels positively correlated with age (P < 0.001). Changes over time in BMI were associated with an inverse correlation in IGFBP-2 concentrations. Furthermore, we found indications of a relationship between low baseline IGFBP-2 levels and mortality. Remarkably, after adjustment for insulin sensitivity, the opposite association was found, as a unit increase of log(IGFBP2) was associated with an increase in the log hazard by 1.43 (95% CI: 0.3–2.6). This accounted for both baseline (P = 0.02) as well as serial (P < 0.001) measurements of IGFBP2. Finally, in this longitudinal study, we found that IGF-I concentrations increased with age (0.82 ± 0.2 (µg/L)/year, P < 0.001).


This is the first study investigating the relationship between IGFBP-2 levels and age in a longitudinal setting. Serum IGFBP-2 levels increase with age after the age of 50 years and evolve in parallel with insulin sensitivity. IGFBP-2 may therefore be a potential marker for insulin sensitivity. We further show that IGFBP-2 levels can predict mortality in this aging population. However, its predictive value for mortality can only be interpreted in relation to insulin sensitivity. After adjustment for insulin sensitivity, high IGFBP-2 levels are predictive of increased mortality.


     European Society of Endocrinology

Article Information


All Time Past Year Past 30 Days
Abstract Views 667 667 167
Full Text Views 108 108 16
PDF Downloads 48 48 14


Related Articles



ToogoodAAShaletSM. Ageing and growth hormone status. Bailliere’s Clinical Endocrinology and Metabolism 1998 12 281296. (https://doi.org/10.1016/S0950-351X(98)80023-2)


YauSWAzarWJSabinMAWertherGARussoVC. IGFBP-2 - taking the lead in growth, metabolism and cancer. Journal of Cell Communication and Signaling 2015 9 125142. (https://doi.org/10.1007/s12079-015-0261-2)


BorstSEMillardWJLowenthalDT. Growth hormone, exercise, and aging: the future of therapy for the frail elderly. Journal of the American Geriatrics Society 1994 42 528535. (https://doi.org/10.1111/j.1532-5415.1994.tb04976.x)


BartkeASunLYLongoV. Somatotropic signaling: trade-offs between growth, reproductive development, and longevity. Physiological Reviews 2013 93 571598. (https://doi.org/10.1152/physrev.00006.2012)


WheatcroftSBKearneyMTShahAMEzzatVAMiellJRModoMWilliamsSCCawthornWPMedina-GomezGVidal-PuigA et al. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007 56 285294. (https://doi.org/10.2337/db06-0436)


HedbackerKBirsoyKWysockiRWAsilmazEAhimaRSFarooqiISFriedmanJM. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metabolism 2010 11 1122. (https://doi.org/10.1016/j.cmet.2009.11.007)


FrystykJSkjaerbaekCVestboEFiskerSOrskovH. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes/Metabolism Research and Reviews 1999 15 314322. (https://doi.org/10.1002/(SICI)1520-7560(199909/10)15:5<314::AID-DMRR56>3.0.CO;2-E)


HealdAHKaushalKSiddalsKWRudenskiASAndersonSGGibsonJM. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Experimental and Clinical Endocrinology and Diabetes 2006 114 371376. (https://doi.org/10.1055/s-2006-924320)


van den BeldAWBlumWFBrugtsMPJanssenJAGrobbeeDELambertsSW. High IGFBP2 levels are not only associated with a better metabolic risk profile but also with increased mortality in elderly men. European Journal of Endocrinology 2012 167 111117. (https://doi.org/10.1530/EJE-12-0160)


FazeliPKLawsonEAPrabhakaranRMillerKKDonohoDAClemmonsDRHerzogDBMisraMKlibanskiA. Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 2010 95 48894897. (https://doi.org/10.1210/jc.2010-0493)


PickardAMcCanceDJ. IGF-binding protein 2: Oncogene of Tumor Suppresor?. Frontiers in Endocrinology 2015 6 25. (https://doi.org/10.3389/fendo.2015.00025)


LiouJMShunCTLiangJTChiuHMChenMJChenCCWangHPWuMSLinJT. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. Journal of Clinical Endocrinology and Metabolism 2010 95 17171725. (https://doi.org/10.1210/jc.2009-2668)


Baron-HaySBoyleFFerrierAScottC. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clinical Cancer Research 2004 10 17961806. (https://doi.org/10.1158/1078-0432.CCR-0672-2)


Probst-HenschNMSteinerJHSchramlPVargaZZurrer-HardiUStorzMKorolDFehrMKFinkDPestalozziBC et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clinical Cancer Research 2010 16 10251032. (https://doi.org/10.1158/1078-0432.CCR-09-0957)


HuDPawlikowskaLKanayaAHsuehWCColbertLNewmanABSatterfieldSRosenCCummingsSRHarrisTB et al. Serum insulin-like growth factor-1 binding proteins 1 and 2 and mortality in older adults: the Health, Aging, and Body Composition Study. Journal of the American Geriatrics Society 2009 57 12131218. (https://doi.org/10.1111/j.1532-5415.2009.02318.x)


ShockNWGreulichRCCostaPTJrAndresRLakattaEGArenbergDTobinJD. Normal Human Aging. Washington D.C.: U.S. Govt. Printing office (1984 edn.). the Baltimore longitudinal Study of aging 84–2450 Ed NIo Health.


LissnerLAndresRMullerDCShimokataH. Body weight variability in men: metabolic rate, health and longevity. International Journal of Obesity 1990 14 373383.


TheodorakisMJCarlsonOMullerDCEganJM. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 2004 27 16921698. (https://doi.org/10.2337/diacare.27.7.1692)


MatsudaMDeFronzoRA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999 22 14621470. (https://doi.org/10.2337/diacare.22.9.1462)


VerbekeGFieuwsSMolenberghsGDavidianM. The analysis of multivariate longitudinal data: a review. Statistical Methods in Medical Research 2017 26 112. (https://doi.org/10.1177/0962280214539862)


RizopoulosDTakkenbergJJ. Tools & techniques – statistics: dealing with time-varying covariates in survival analysis – joint models versus Cox models. EuroIntervention 2014 10 285288. (https://doi.org/10.4244/EIJV10I2A47)


BlumWFBreierBH. Radioimmunoassays for IGFs and IGFBPs. Growth Regulation 1994 4 (Supplement 1) 1119.


JonesJIDoerrMEClemmonsDR. Cell migration: interactions among integrins, IGFs and IGFBPs. Progress in Growth Factor Research 1995 6 319327. (https://doi.org/10.1016/0955-2235(95)00015-1)


LiZMiardSLaplanteMSonenbergNPicardF. Insulin stimulates IGFBP-2 expression in 3T3-L1 adipocytes through the PI3K/mTOR pathway. Molecular and Cellular Endocrinology 2012 358 6368. (https://doi.org/10.1016/j.mce.2012.02.022)


AsilmazECohenPMiyazakiMDobrzynPUekiKFayzikhodjaevaGSoukasAAKahnCRNtambiJMSocciND et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. Journal of Clinical Investigation 2004 113 414424. (https://doi.org/10.1172/JCI200419511)


YauSWHenryBARussoVCMcConellGKClarkeIJWertherGASabinMA. Leptin enhances insulin sensitivity by direct and sympathetic nervous system regulation of muscle IGFBP-2 expression: evidence from nonrodent models. Endocrinology 2014 155 21332143. (https://doi.org/10.1210/en.2013-2099)


YoungNJMetcalfeCGunnellDRowlandsMALaneJAGilbertRAveryKNDavisMNealDEHamdyFC et al. A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, And IGFBP-3 in men in the United Kingdom. Cancer Causes and Control 2012 23 907917. (https://doi.org/10.1007/s10552-012-9961-6)


Closa-MonasteroloRFerreNLuqueVZaragoza-JordanaMGroteVWeberMKoletzkoBSochaPGruszfeldDJanasR et al. Sex differences in the endocrine system in response to protein intake early in life. American Journal of Clinical Nutrition 2011 94 1920S1927S. (https://doi.org/10.3945/ajcn.110.001123)


BlumWFHornNKratzschJJorgensenJOJuulATealeDMohnikeKRankeMB. Clinical studies of IGFBP-2 by radioimmunoassay. Growth Regulation 1993 3 100104.


MattssonASvenssonDSchuettBOsterzielKJRankeMB. Multidimensional reference regions for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum of healthy adults. Growth Hormone and IGF Research 2008 18 506516. (https://doi.org/10.1016/j.ghir.2008.04.005)


van den BeldAWBlumWFPolsHAGrobbeeDELambertsSW. Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men. European Journal of Endocrinology 2003 148 627634. (https://doi.org/10.1530/eje.0.1480627)


XiGSolumMAWaiCMaileLARosenCJClemmonsDR. The heparin-binding domains of IGFBP-2 mediate its inhibitory effect on preadipocyte differentiation and fat development in male mice. Endocrinology 2013 154 41464157. (https://doi.org/10.1210/en.2013-1236)


YaoXSunSZhouXGuoWZhangL. IGF-binding protein 2 is a candidate target of therapeutic potential in cancer. Tumour Biology 2016 37 14511459. (https://doi.org/10.1007/s13277-015-4561-1)


CountsDRGwirtsmanHCarlssonLMLesemMCutlerGBJr. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. Journal of Clinical Endocrinology and Metabolism 1992 75 762767.


Di SommaCBrunelliVSavanelliMCScaranoESavastanoSLombardiGColaoA. Somatopause: state of the art. Minerva Endocrinol 2011 36 243255.


SandersJLGuoWO’MearaESKaplanRCPollakMNBartzTMNewmanABFriedLPCappolaAR. Trajectories of IGF-I predict mortality in older adults: the cardiovascular Health Study. Journals of Gerontology: Series A Biological Sciences and Medical Sciences 2018 73 953959. (https://doi.org/10.1093/gerona/glx143)


BannDHollyJMPLashenHHardyRAdamsJKuhDOngKKBen-ShlomoY. Changes in insulin-like growth factor-I and -II associated with fat but not lean mass in early old age. Obesity 2015 23 692698. (https://doi.org/10.1002/oby.21002)


KaplanRCBuzkovaPCappolaARStricklerHDMcGinnAPMercerLDArnoldAMPollakMNNewmanAB. Decline in circulating insulin-like growth factors and mortality in older adults: cardiovascular health study all-stars study. Journal of Clinical Endocrinology and Metabolism 2012 97 19701976. (https://doi.org/10.1210/jc.2011-2967)


Google Scholar